laitimes

Hengrui Pharmaceutical: Famitinib malate capsules and carellizumab for injection obtained the approval notice of drug clinical trials

Hengrui Pharmaceutical (600276) announced that the company and its subsidiary Suzhou Shengdia Biopharmaceutical Co., Ltd. have received the approval of the State Drug Administration to issue the "Drug Clinical Trial Approval Notice" on famitinib malate capsules and carellizumab for injection, and will carry out clinical trials in the near future.

Read on